Interleukin Genetics, Inc. Reports Third Quarter 2007 Financi...(ongoing research projects. There were...)

There were no significant changes in selling, general and administrative expenses for the period. Interleukin reported selling, general and administrative expenses $1.2 million for the quarter ended September 2007, compared to $1.2 million for the same period last year.

Balance Sheet

Interleukin reported cash and cash equivalents of $8.0 million as of September 30, 2007, compared to $10.1 million at December 31, 2006. Under its credit facility the Company had access to $14.3 million on September 30, 2007.

ILI Earnings Conference Call

To access the live call on November 7, 2007 at 4:30 PM EST, dial (800) 366-3964 (domestic) or (303) 205-0055 (international). The call will also be available live via webcast at http://www.ilgenetics.com.

Replay access of the teleconference will be available for two weeks following the call by calling (800) 405-2236 (domestic) or (303) 590-3000 (international). The passcode for the replay is 11101550. The webcast will be archived following the call at http://www.ilgenetics.com.

About Interleukin

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sol
'/>"/>